Advisers to Congress on Medicare payment issues last week discussed reimbursement issues for biosimilars because biosimilars are really and finally happening.
that are biologically similar to brand name or reference product biologics. The
abbreviated approval process for biosimilars was set out in the Biologic Price
Competition and Innovation Act in 2010, and it took five years before the first
biosimilar was approved. Now there are four approved biosimilars with more applying
“This is no longer
hypothetical,” said Jack Hoadley, a research professor at the Georgetown
University Health Policy Institute, at the
meeting of the Medicare Payment
Advisory Commission ( MedPAC)
on Oct. 7.
“Unlike the situation where this was discussed in previous years, biosimilars [now] have been approved by the Food and Drug Administration. They're out there. And our goal is to see how to make it easier for consumers to access biosimilars without all the hoops that have currently to be gone through today,” Hoadley said.
At their meeting, Hoadley and
noted that some incentives and discounts that are available under Medicare for
use of brand name, or
reference, biologic s can make them seem less
expensive than biosimilars, which are supposed to
be a lower-cost alternative.
Solutions the commissioners discussed were extending to biosimilars the coverage gap discount that currently applies to branded/reference biologics, and ensuring that plan incentives encourage the use of lower-cost products.
You can read my article here.
discussed other topics as well. In an article by Bloomberg BNA reporter Michael D. Williamson,
he describes how the commissioners said accountable
care organizations— groups
of doctors, hospitals and other providers working together to provide better,
more coordinated care with the aim of lowering Medicare’s costs— haven’t
created substantial savings for the government and some should be pushed to
take on more risk. Michael’s article is here.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)